CorMedix Q3 2026 earnings
CorMedix reports Q3 2026 revenue of $102.5 million, raising Adjusted EBITDA guidance to $125-$140 million while narrowing Cash OpEx guidance to $145-$155 million.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $102.5 million | +157.6% | +0.6% | Ex. 99.1, Financial Highlights |
| EPS (GAAP) | $0.33 | +13.8% | +0.0% | Ex. 99.1, Financial Highlights |
| EPS (adjusted) | $0.58 | +158.9% | +100.0% | Ex. 99.1, Financial Highlights |
| Net income | $26.0 million | +31.2% | +0.0% | Ex. 99.1, Financial Highlights |
| Adj. EBITDA | $58.7 million | +161.8% | +0.0% | Ex. 99.1, Financial Highlights |
| Adj. EBITDA margin | 57.2% | +35.6 pp | +1.2 pp | Ex. 99.1, Financial Highlights |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| DefenCath | $66.1 million | +66.2% | 64.5% | Driven by continued utilization by large outpatient dialysis customers |
| Melinta portfolio | $35.8 million | N/A | 34.9% | Acquired portfolio contribution |
Margins and costs
- Gross margin 75.7% (prior 37.2%, change +38.5 pp)
- Operating expenses $34.2 million (+87% YoY)
- One-offs in the quarter Change in contingent consideration: -$6.7 million; Unrealized gain on marketable equity security: +$2.5 million; Merger related and reorg costs: +$1.2 million
- Effective tax rate 32.9% (prior-year 2.6%, year-to-date 31.5%)
- Non-GAAP bridge Adds back interest, taxes, depreciation, stock-based compensation, merger costs, and other expenses to GAAP net income.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash and cash equivalents | $256.7 million | $256.7 million | $144.8 million | +77.1% |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Total revenue | $325 to $345 million | $325 to $345 million | No change |
| Adjusted EBITDA | $125 to $140 million | $125 to $140 million | No change |
| Cash OpEx | $145 to $155 million | $145 to $155 million | No change |
What drove it
- Revenue story Q3 2026 revenue increased 157.6% year-over-year to $102.5 million, driven by DefenCath sales of $66.1 million (+66.2%) and the Melinta portfolio contribution of $35.8 million.
- EPS story GAAP EPS increased 13.8% year-over-year to $0.33, while Adjusted EPS increased 158.9% to $0.58, driven by revenue growth and a significant expansion in Adjusted EBITDA margin.
- One-off check Change in contingent consideration of -$6.7 million and unrealized gain on marketable equity security of +$2.5 million are non-recurring items impacting net income.
The good
- Revenue growth of 157.6% year-over-year
- Adjusted EBITDA margin expansion of 35.6 percentage points year-over-year
- Strong cash position of $256.7 million
The bad
- Operating expenses increased 87% year-over-year due to the Melinta acquisition
The ugly
- none
Open questions
- The release provides a business update but does not disclose the specific Q3 financial results (revenue, EPS, etc.).
- The release does not provide a reconciliation of Adjusted EBITDA for Q3 2026.
Full release
CorMedix (CRMD) earnings release, November 2, 2026
CORMEDIX
THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD
Quarter
Cash Position
Parsippany,
NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call expected to be held on November 12, 2026 to discuss the Company’s complete quarterly financial performance.
Business Updates
About CorMedix
CorMedix
Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers.
For more information visit: www.cormedix.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties. Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,”
“believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,”
“may,” “plan,” “project,” “seek,” “should,” “target,” “will,”
“would,” and similar expressions or variations intended to identify forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or CorMedix’s prospects should be considered forward-looking statements including, but not limited to statements regarding financial and business guidance; sales, revenue and operating expense estimates; the 2027 post-TDAPA Add-on changes for DefenCath; and CorMedix’s forecasts and projections for the 2027 Add-on trajectory.
CorMedix estimates for the 2027 Add-on are subject to several factors and assumptions, including known historical utilization and pricing data, DefenCath maintaining fee-for-service utilization in line with current trends, and the method by which CMS will apply certain utilization data in the Add-on calculations.
Changes in customer utilization patterns, including fee-for-service utilization, changes in pricing, or differences between CMS’s application of its calculation methodology and the Company’s assumptions could cause the actual CMS-determined quarterly Add-on rates and the resulting full-year average to differ materially from CorMedix’s estimates. Increased reimbursement to dialysis facilities may not result in corresponding increases in CorMedix's realized pricing, product utilization or revenue. Additional risks include continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals and reporting obligations related thereto; and the expiration or loss of intellectual property protection for certain of the Company's products and competition from generic and biosimilar products. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, and readers are directed to the Risk Factors identified in CorMedix’s filings with the SEC, including its most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from CorMedix.
CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and such forward-looking statements speak only as of the date of this press release. Investors should not place undue reliance on these statements. CorMedix does not adopt or endorse, and undertakes no obligation to comment on or correct, any projections, estimates or statements regarding its business or results of operations that are made by third parties, including analysts and customers, except as required by law. CorMedix assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors daniel@lifesciadvisors.com
(617) 430-7576